Analgesic Compounding - Laboratory Training
As it stands today, first-line treatments for pain management are often associated with adverse systemic effects, including gastrointestinal
erosions, constipation, central nervous system depression, addiction, and tolerance. Moreover, many currently available commercial
analgesics are limited in therapeutic efficacy, rendering many pain symptoms left untreated or inadequately managed. With compounded
topical creams and gels, patients are better able to target the site of action through local application to affected regions, limiting systemic
reactions and in many cases, improving therapeutic outcome. In addition, compounders can develop low-dose multi-drug formulations
that reach multiple nociceptive pathways, further optimizing targeted effect and ultimately therapeutic payoff.
The objective of this laboratory training is to expose pharmacists and technicians to the hands-on experience of compounding dosage forms
common to the niche market of analgesic therapy, notably creams, gels, and pastes. Participants will learn how to optimize the efficiency
and quality of their compounding process by practicing novel compounding techniques and implementing innovative technologies and
- Clonidine HCl 0.16%, Gabapentin 6%, Ketamine† HCl 5.75 % Topical Cream
- Diclofenac Sodium 5% Topical Gel
- Capsaicin 0.025%, Lidocaine 6%, Tetracaine 4% Dental Paste
Note: Formulas are subject to change.
†Controlled substances will be replaced by non-controlled substances.
DURATION: 4 HOURS
Tammy Nguyen, BPharm
Compounding Pharmacist, MEDISCA Australia.
Rebecca O’Grady, BPharm, GradCertPharmPrac
Technical Support Services Representative, MEDISCA Australia.
Patricia Ullmann, BPharm
Training and Support Services Manager, MEDISCA Australia.
Activity material is Copyright© 2008-2019 LP3 Network Inc.
Full attendance and participation is required to receive a Certificate of Attainment.
DECLARATIONS AND DISCLOSURES
This activity is independent of any known bias, prejudice or commercial interest. Both MEDISCA Australia and LP3 Network Inc. assist
with the marketing of this activity. LP3 Network Inc. is an independent corporation. LP3 Network Inc. has an established agreement with
MEDISCA AUSTRALIA ensuring that it has no influence on LP3 Network Inc. as it relates to activity offerings.
An unrestricted educational grant has been provided by MEDISCA Inc. toward the purchase of electromechanical equipment, reusable
and disposable devices, protective and safety supplies, and chemicals specific to compounded medications prepared during laboratory
Special rates for hotel accommodations have been arranged for activity participants. Payment for hotel accommodations is at the expense
of the activity participant.
FOOD AND BEVERAGE
As a matter of activity programming, meals and refreshments during live activities have been provided by MEDISCA Australia.
CANCELLATION AND REFUND POLICY
A written request must be sent to MEDISCA Australia requesting a ‘Cancellation without Transfer’ to an alternate live activity event date. If
cancellation occurs at greater than or equal to 31 days from the live activity event date, then the registrant will receive a 75% refund; 15-30
days is a 50% refund; and less than or equal to 14 days will result in no refund.
The transfer policy is only in effect if requested less than or equal to 15 days post original live activity event date. Failure to submit the
“Transfer Request” within 15 days post original live activity event date will default to the “Cancellation and Refund Policy”. The transfer
policy can only be applied one (1) time. Transfer to a new live activity event date must be within the current calendar year. Failure to attend
the new live activity event will result in no refund and will no longer be transferable. Confirmation of the new activity date is subject to
approval by MEDISCA Australia based on the number of available seats within the selected live activity event.